# Castle Biosciences Inc: financial statements, quarterly

CSTL · Nasdaq · CIK 1447362 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cstl.md) · [Financials](/companies/cstl/financials.md) · [Filings](/companies/cstl/filings.md) · [Insiders](/companies/cstl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cstl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [61.5](/filings/0001447362-24-000169.md) | [66.1 d](/filings/0001628280-26-012272.md) | [73.0](/filings/0001447362-25-000069.md) | [87.0](/filings/0001447362-25-000097.md) | [85.8](/filings/0001628280-25-048254.md) | [86.3 d](/filings/0001628280-26-012272.md) | [88.0](/filings/0001628280-26-031263.md) | [86.2](/filings/0001628280-26-051052.md) | [83.0](/filings/0001628280-25-048254.md) | [87.0 d](/filings/0001628280-26-012272.md) | [83.7](/filings/0001628280-26-031263.md) | [104](/filings/0001628280-26-051052.md) |
| Cost of revenue | $m | [11.3](/filings/0001447362-24-000169.md) | [12.4 d](/filings/0001628280-26-012272.md) | [13.9](/filings/0001447362-25-000069.md) | [14.5](/filings/0001447362-25-000097.md) | [15.6](/filings/0001628280-25-048254.md) | [16.2 d](/filings/0001628280-26-012272.md) | [16.4](/filings/0001628280-26-031263.md) | [17.6](/filings/0001628280-26-051052.md) | [18.7](/filings/0001628280-25-048254.md) | [18.3 d](/filings/0001628280-26-012272.md) | [20.5](/filings/0001628280-26-031263.md) | [23.7](/filings/0001628280-26-051052.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [12.9](/filings/0001447362-24-000169.md) | [13.0 d](/filings/0001628280-26-012272.md) | [13.8](/filings/0001447362-25-000069.md) | [14.1](/filings/0001447362-25-000097.md) | [12.3](/filings/0001628280-25-048254.md) | [11.8 d](/filings/0001628280-26-012272.md) | [12.6](/filings/0001628280-26-031263.md) | [12.8](/filings/0001628280-26-051052.md) | [13.0](/filings/0001628280-25-048254.md) | [13.5 d](/filings/0001628280-26-012272.md) | [14.4](/filings/0001628280-26-031263.md) | [14.5](/filings/0001628280-26-051052.md) |
| Selling, general and administrative | $m | [44.6](/filings/0001447362-24-000169.md) | [44.1 d](/filings/0001628280-26-012272.md) | [48.5](/filings/0001447362-25-000069.md) | [51.1](/filings/0001447362-25-000097.md) | [50.5](/filings/0001628280-25-048254.md) | [50.0 d](/filings/0001628280-26-012272.md) | [58.6](/filings/0001628280-26-031263.md) | [58.1](/filings/0001628280-26-051052.md) | [55.9](/filings/0001628280-25-048254.md) | [56.7 d](/filings/0001628280-26-012272.md) | [64.9](/filings/0001628280-26-031263.md) | [66.1](/filings/0001628280-26-051052.md) |
| Operating income | $m | [(9.6)](/filings/0001447362-24-000169.md) | [(5.7) d](/filings/0001628280-26-012272.md) | [(5.5)](/filings/0001447362-25-000069.md) | [5.0](/filings/0001447362-25-000097.md) | [5.1](/filings/0001628280-25-048254.md) | [4.1 d](/filings/0001628280-26-012272.md) | [(27.9)](/filings/0001628280-26-031263.md) | [(4.3)](/filings/0001628280-26-051052.md) | [(6.8)](/filings/0001628280-25-048254.md) | [(3.8) d](/filings/0001628280-26-012272.md) | [(18.4)](/filings/0001628280-26-031263.md) | [(3.1)](/filings/0001628280-26-051052.md) |
| Interest expense | $m | [0.0](/filings/0001447362-23-000147.md) | [0.0 d](/filings/0001447362-24-000017.md) | [0.0](/filings/0001447362-25-000069.md) | [0.2](/filings/0001447362-25-000097.md) | [0.2](/filings/0001447362-24-000169.md) | [0.2 d](/filings/0001628280-26-012272.md) | [0.0](/filings/0001447362-25-000069.md) | [0.0](/filings/0001447362-25-000097.md) | [0.0](/filings/0001628280-25-048254.md) | [0.0 d](/filings/0001628280-26-012272.md) | [0.1](/filings/0001628280-26-031263.md) | [0.2](/filings/0001628280-26-051052.md) |
| Income tax | $m | [0.0](/filings/0001447362-24-000169.md) | [0.0 d](/filings/0001628280-26-012272.md) | [0.0](/filings/0001447362-25-000069.md) | [(1.0)](/filings/0001447362-25-000097.md) | [6.0](/filings/0001628280-25-048254.md) | [(1.7) d](/filings/0001628280-26-012272.md) | [(0.4)](/filings/0001628280-26-031263.md) | [(4.7)](/filings/0001628280-26-051052.md) | [0.1](/filings/0001628280-25-048254.md) | [(0.4) d](/filings/0001628280-26-012272.md) | [0.1](/filings/0001628280-26-031263.md) | [0.4](/filings/0001628280-26-051052.md) |
| Net income | $m | [(6.9)](/filings/0001447362-24-000169.md) | [(2.6) d](/filings/0001628280-26-012272.md) | [(2.5)](/filings/0001628280-25-048254.md) | [8.9](/filings/0001628280-25-048254.md) | [2.3](/filings/0001628280-25-048254.md) | [9.6 d](/filings/0001628280-26-012272.md) | [(25.8)](/filings/0001628280-26-051052.md) | [4.5](/filings/0001628280-26-051052.md) | [(0.5)](/filings/0001628280-25-048254.md) | [(2.3) d](/filings/0001628280-26-012272.md) | [(14.5)](/filings/0001628280-26-051052.md) | [(2.1)](/filings/0001628280-26-051052.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001447362-24-000169.md) | not reported | [(0.09)](/filings/0001447362-25-000069.md) | [0.31](/filings/0001447362-25-000097.md) | [0.08](/filings/0001628280-25-048254.md) | not reported | [(0.90)](/filings/0001628280-26-031263.md) | [0.15](/filings/0001628280-26-051052.md) | [(0.02)](/filings/0001628280-25-048254.md) | not reported | [(0.49)](/filings/0001628280-26-031263.md) | [(0.07)](/filings/0001628280-26-051052.md) |
| Basic EPS | $ per share | [(0.26)](/filings/0001447362-24-000169.md) | not reported | [(0.09)](/filings/0001447362-25-000069.md) | [0.32](/filings/0001447362-25-000097.md) | [0.08](/filings/0001628280-25-048254.md) | not reported | [(0.90)](/filings/0001628280-26-031263.md) | [0.16](/filings/0001628280-26-051052.md) | [(0.02)](/filings/0001628280-25-048254.md) | not reported | [(0.49)](/filings/0001628280-26-031263.md) | [(0.07)](/filings/0001628280-26-051052.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [91.2](/filings/0001447362-23-000147.md) | [98.8](/filings/0001447362-25-000031.md) | [82.9](/filings/0001447362-24-000060.md) | [85.6](/filings/0001447362-24-000122.md) | [95.0](/filings/0001447362-24-000169.md) | [120](/filings/0001628280-26-012272.md) | [89.7](/filings/0001447362-25-000069.md) | [82.2](/filings/0001447362-25-000097.md) | [85.6](/filings/0001628280-25-048254.md) | [117](/filings/0001628280-26-051052.md) | [63.8](/filings/0001628280-26-031263.md) | [62.1](/filings/0001628280-26-051052.md) |
| Current assets | $m | [280](/filings/0001447362-23-000147.md) | [296](/filings/0001447362-25-000031.md) | [296](/filings/0001447362-24-000060.md) | [320](/filings/0001447362-24-000122.md) | [345](/filings/0001447362-24-000169.md) | [360](/filings/0001628280-26-012272.md) | [349](/filings/0001447362-25-000069.md) | [349](/filings/0001447362-25-000097.md) | [358](/filings/0001628280-25-048254.md) | [361](/filings/0001628280-26-051052.md) | [329](/filings/0001628280-26-031263.md) | [341](/filings/0001628280-26-051052.md) |
| Total assets | $m | [436](/filings/0001447362-23-000147.md) | [453](/filings/0001447362-25-000031.md) | [459](/filings/0001447362-24-000060.md) | [487](/filings/0001447362-24-000122.md) | [515](/filings/0001447362-24-000169.md) | [531](/filings/0001628280-26-012272.md) | [502](/filings/0001447362-25-000069.md) | [545](/filings/0001447362-25-000097.md) | [563](/filings/0001628280-25-048254.md) | [579](/filings/0001628280-26-051052.md) | [548](/filings/0001628280-26-031263.md) | [561](/filings/0001628280-26-051052.md) |
| Current liabilities | $m | [36.3](/filings/0001447362-23-000147.md) | [47.7](/filings/0001447362-25-000031.md) | [32.0](/filings/0001447362-24-000060.md) | [39.5](/filings/0001447362-24-000122.md) | [44.3](/filings/0001447362-24-000169.md) | [49.4](/filings/0001628280-26-012272.md) | [37.3](/filings/0001447362-25-000069.md) | [50.9](/filings/0001447362-25-000097.md) | [55.3](/filings/0001628280-25-048254.md) | [68.7](/filings/0001628280-26-051052.md) | [48.8](/filings/0001628280-26-031263.md) | [56.5](/filings/0001628280-26-051052.md) |
| Total liabilities | $m | [50.2](/filings/0001447362-23-000147.md) | [62.1](/filings/0001447362-25-000031.md) | [56.0](/filings/0001447362-24-000060.md) | [63.4](/filings/0001447362-24-000122.md) | [73.5](/filings/0001447362-24-000169.md) | [75.4](/filings/0001628280-26-012272.md) | [61.4](/filings/0001447362-25-000069.md) | [89.4](/filings/0001447362-25-000097.md) | [95.7](/filings/0001628280-25-048254.md) | [108](/filings/0001628280-26-051052.md) | [86.4](/filings/0001628280-26-031263.md) | [91.1](/filings/0001628280-26-051052.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001447362-25-000031.md) | [10.0](/filings/0001447362-24-000060.md) | [10.0](/filings/0001447362-24-000122.md) | [10.0](/filings/0001447362-24-000169.md) | [9.7](/filings/0001628280-26-012272.md) | [8.9](/filings/0001447362-25-000069.md) | [8.1](/filings/0001447362-25-000097.md) | [10.0](/filings/0001628280-25-048254.md) | [9.6](/filings/0001628280-26-051052.md) | [8.4](/filings/0001628280-26-031263.md) | [7.2](/filings/0001628280-26-051052.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001447362-25-000031.md) | [0.0](/filings/0001447362-24-000060.md) | [0.0](/filings/0001447362-24-000122.md) | [0.0](/filings/0001447362-24-000169.md) | [0.3](/filings/0001628280-26-012272.md) | [1.1](/filings/0001447362-25-000069.md) | [1.9](/filings/0001447362-25-000097.md) | [0.0](/filings/0001628280-25-048254.md) | [0.4](/filings/0001628280-26-051052.md) | [1.7](/filings/0001628280-26-031263.md) | [2.9](/filings/0001628280-26-051052.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [386](/filings/0001447362-24-000169.md) | [391](/filings/0001628280-26-012272.md) | [402](/filings/0001628280-25-048254.md) | [424](/filings/0001628280-25-048254.md) | [441](/filings/0001628280-25-048254.md) | [456](/filings/0001628280-26-051052.md) | [440](/filings/0001628280-26-051052.md) | [455](/filings/0001628280-26-051052.md) | [467](/filings/0001628280-25-048254.md) | [471](/filings/0001628280-26-051052.md) | [461](/filings/0001628280-26-051052.md) | [470](/filings/0001628280-26-051052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [5.0 d](/filings/0001447362-24-000169.md) | [18.6 d](/filings/0001628280-26-012272.md) | [(6.8)](/filings/0001447362-25-000069.md) | [24.0 d](/filings/0001447362-25-000097.md) | [23.3 d](/filings/0001628280-25-048254.md) | [24.4 d](/filings/0001628280-26-012272.md) | [(6.0)](/filings/0001628280-26-031263.md) | [20.8 d](/filings/0001628280-26-051052.md) | [22.6 d](/filings/0001628280-25-048254.md) | [26.9 d](/filings/0001628280-26-012272.md) | [(22.1)](/filings/0001628280-26-031263.md) | [15.2 d](/filings/0001628280-26-051052.md) |
| Capital expenditure | $m | [2.5 d](/filings/0001447362-24-000169.md) | [3.8 d](/filings/0001628280-26-012272.md) | [9.2](/filings/0001447362-25-000069.md) | [5.2 d](/filings/0001447362-25-000097.md) | [6.4 d](/filings/0001628280-25-048254.md) | [7.6 d](/filings/0001628280-26-012272.md) | [4.7](/filings/0001628280-26-031263.md) | [9.3 d](/filings/0001628280-26-051052.md) | [14.8 d](/filings/0001628280-25-048254.md) | [7.2 d](/filings/0001628280-26-012272.md) | [12.5](/filings/0001628280-26-031263.md) | [8.7 d](/filings/0001628280-26-051052.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.3](/filings/0001447362-23-000147.md) | [26.6](/filings/0001447362-24-000060.md) | [26.7](/filings/0001447362-24-000122.md) | [26.8](/filings/0001447362-24-000169.md) | [27.5](/filings/0001447362-25-000069.md) | [28.7](/filings/0001447362-25-000097.md) | [29.4](/filings/0001628280-25-048254.md) | [28.6](/filings/0001628280-26-031263.md) | [29.5](/filings/0001628280-26-051052.md) | [29.1](/filings/0001628280-25-048254.md) | [29.9](/filings/0001628280-26-031263.md) | [30.4](/filings/0001628280-26-051052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,549,507 at 2026-07-23, from the cover of the [10-Q filed 2026-07-30](/filings/0001628280-26-051052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.